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Breast Cancer (BC) skin metastases represent a challenging clinical scenario. Although
they usually arise when other distant metastases are already present, they may also
represent a form of locoregional recurrence (LRR). Systemic therapy in this setting
may have a role both in case a radical locoregional approach is unfeasible in order to
achieve disease control, and as adjuvant strategy after radical removal of cutaneous
lesions, in order to prevent or delay subsequent disease spread. Systemic therapy for
HER2+ metastatic BC (MBC) currently relies on anti-HER2 targeted agents. In this
context TDM1 is an option in trastuzumab-resistant patients.Here we present 2 cases
of isolated skin metastases in patients with HER2+ BC progressing during or early after
trastuzumab-based therapy, showing impressive responses to TDM1. We hypothesize
that the unique properties of skin immune microenvironment may explain the failure of
trastuzumab, which exerts its action also through immunological mechanisms, and the
subsequent outlier responses to TDM1, that relies on a partially different mechanism of
action.
Keywords: metastatic breast cancer, skin metastasis, T-DM1, adotrastuzumab, emtansine, immune
microenvironment
INTRODUCTION
Although skin metastases arising from non-skin solid malignancies are relatively uncommon (1, 2),
they are considerably more frequent among breast cancer (BC) patients compared to other solid
tumors, with an overall incidence of ∼24% in the largest reported series (2). Skin relapse usually
represents a late stage in the course of BC natural history, occurring in most cases when other
distant metastases are already present, and it is associated with poor survival rates (2). In this
context, the use of systemic therapeutic approach plays a major role. Indeed, the administration
of either chemotherapy (CT), endocrine therapy (ET), targeted agents or combinations of them,
is aimed at keeping systemic disease under control, especially in case of simultaneous visceral
involvement.
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However, cutaneous metastases may also appear as a form
of isolated locoregional recurrence (LRR) (3–5). When surgical
approach is not feasible, palliative systemic treatment is aimed
at delaying disease dissemination to other organs/sites and
local complications and can be integrated with palliative
radiotherapy. However, sometimes, when a radical excision of
cutaneous metastases is feasible upfront, it may be considered
as the first choice. In this context, systemic therapy may
play a role as “adjuvant” treatment after skin metastasis
excision. Evidence from the randomized CALOR study showed
that “adjuvant” CT after complete excision of BC LRR
prolonged both DFS and OS especially in case of HR-
BC (6).
In this paper we focused on cases of skin metastases
occurring in HER2+ BC patients. Even though HER2-positive
(HER2+) metastatic breast cancer (MBC) still represents an
incurable disease, the introduction of anti-HER2 targeted agents
has dramatically altered its natural history, with increasing
improvements in survival rates (7–9).
In the pre-trastuzumab era, HER2 positivity represented an
independent predictor for LRR (5, 10). However, after the
introduction of anti-HER2 targeted therapy, incidence of LRR
in HER2+ patients has dramatically decreased. Indeed, it has
recently been reported that the 5y-cumulative incidence of chest
wall recurrence as first site of recurrence after mastectomy
(with or without synchronous distant metastases) is lower
among HER2+ (11, 12) compared to HER2 negative BC
patients. In addition, it has been reported that skin represents
the first distant site of relapse in ∼8% of HER2+ BC
patients (13).
Evidence from several randomized clinical trials strongly
suggest that there is a survival benefit from continuing some sort
of HER2 blockade for metastatic disease in case of progression
during or after anti-HER2 targeted therapies (14–17).
Ado-trastuzumab emtasine (TDM-1) is an anti-HER2
targeted antibody conjugate, currently indicated for the
treatment of HER2+ MBC patients that have either received
trastuzumab for metastatic disease or developped disease
recurrence during or within 6 months from the completion
of adjuvant trastuzumab-based therapy (18). This molecule
consists of trastuzumab plus the cytotoxic DM1 (emtasine), the
first selectively and specifically delivering the second inside the
HER2+ cancer cells through receptor-mediated endocytosis.
Once released inside the tumor cells, DM1 exerts its cytotoxic
effect through several mechanisms, such as mitotic arrest,
apoptosis, mitotic catastrophe, and disruption of intracellular
trafficking, ultimately causing cell death (19).
Abbreviations: BC, breast cancer; LRR, locoregional recurrence; CT,
chemotherapy; ET, endocrine therapy; DFS, disease-free survival; OS, overall
survival; HR, hormone receptor; MBC, metastatic breast cancer; T-DM1,
trastuzumab emtansine; HER2+, Human epidermal growth factor receptor-
2 positive; IHC, immunohistochemistry; IDC, invasive ductal carcinoma;
RT, radiotherapy; DFI, disease-free interval; PFS, progression-free survival;
NK, natural killer cell; CTLA-4/PD-1, cytotoxic T-lymphocyte–associated
antigen 4/ programmed death 1; FOXP3, Forkhead box protein 3; MHC, major
histocompatibility complex; RFS, relapse-free survival.
Herein we describe 2 cases of patients with HER2+ cutaneous
disease showing progression during or after trastuzumab-
containing regimens and subsequent exceptional responses to
TDM1.
CASE PRESENTATION
Patient 1
A 61 years old post-menopausal woman was admitted to our
hospital for a locally advanced tumor in the left breast, with
clinical involvement of axillary nodes (cT3N3). Pathological
evaluation of a core needle biopsy revealed the presence of
HR-/HER2+ invasive ductal carcinoma (IDC). The patient
received neoadjuvant CT with 12 cycles of weekly paclitaxel
plus trastuzumab followed by 4 cycles of cyclophosphamide,
epirubicin, and fluorouracil (FEC). She then underwent left
mastectomy plus axillary node dissection (AND). Pathological
study of the surgical specimen showed scattered foci of ductal
carcinoma in situ, with no residual disease on axillary nodes
(ypTisN0). The patient also underwent radiotherapy (RT) to the
chest wall and supra-clavicular fossa. In addition, she received
trastuzumab to complete 1 year.
Unfortunately, while being treated with trastuzumab, a red
wide cutaneous rash appeared on her left chest wall. A biopsy of
such lesions confirmed the presence of HER2+ skin recurrence.
A restaging CT scan did not show any other sign of distant
metastasis. TDM1 was therefore initiated. Over the course of
4 weeks, the rash completely resolved. It has been 45 cycles of
TDM1 and the patient is still disease-free (Figure 1).
Patient 2
A 39 years old pre-menopausal woman came to our attention
with a locally advanced BC. The pathological evaluation revealed
the presence of HR-/HER2+ IDC (cT3N2). The patient initially
received 3 cycles of neoadjuvant FEC followed by docetaxel
concurrent with trastuzumab; docetaxel was discontinued due to
anaphylactic reaction. She then underwent left mastectomy plus
AND. The pathological study of the surgical specimen reported
the presence of scattered foci of residual IDC in the breast and
the presence of metastasis in four axillary nodes (ypT1micN2).
After surgery, 1 year of trastuzumab treatment was completed.
The patient also underwent RT to the chest wall and sovra-
clavicular fossa. After 12 months from the end of adjuvant
trastuzumab, the patient experienced isolated skin relapse. In
particular, she presented with itchy erythematous skin lesions on
her left chest wall. Since a restaging PET did not reported any sign
of distant metastatic disease, a wide cutaneous surgical excision
was performed. Pathological study of the surgical specimen
confirmed the presence of HR-/HER2+ skin recurrence.
The patient was then offered systemic therapy with CT plus
an anti HER2 agent. However, she refused treatment. The patient
was therefore strictly followed-up.
However, after a disease-free interval (DFI) of 4 months,
the patient experienced a second skin relapse, with a wide
erythematous rash appearing on her trunk. Systemic therapy
with trastuzumab plus vinorelbine was therefore administered.
Unfortunately, 5 months later, the patient experienced a
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FIGURE 1 | Evolution of Case 1-cutaneous metastasis: (A) before TDM1 initiation, (B) after 3 courses of TDM1, (C) after 45 courses of TDM1.
cutaneous disease progression, consisting in an increasing in size
of pre-existing skin lesions and appearance of new skin lesions on
the antero-lateral abdominal wall. TDM1 was then initiated. Two
months later, a complete response was achieved. After 17 cycles
of TDM1, the patient decided to stop treatment. After 9 months
since TDM1 had been discontinued the patient was still disease
free (Figure 2).
DISCUSSION
These two cases show outlier responses of skin metastases to the
anti-HER2 agent TDM1 following progression during or after
trastuzumab-based therapy.
The introduction of anti-HER2 treatments has dramatically
changed the outcome of HER2+ BC patients. However, still
some patients relapse despite adequate treatment for early disease
and still some patients with advanced disease experience poor
outcome.
In particular, patients experiencing rapid progression on or
after adjuvant trastuzumab or first-line anti-HER2 treatment
in metastatic disease represent a challenging clinical scenario.
Moreover, as previously discussed, cutaneous metastases
represent a clinical challenge.
In all cases described herein, patients developed cutaneous
lesions in the form of erythematous rash. This appears to be in
agreement with a recent retrospective analysis that suggested that
the patterns of skin involvement might reflect BC subtype, with
erythematous plaques predominantly shown in HER2+ and TN
BC, and skin ulceration or mass-forming lesions more frequently
observed in HR+ BC (20).
All the cases presented here experienced relapse or
progression during trastuzumab.
T-DM1 is a standard treatment in patients progressing on or
early after trastuzumab, with median progression-free survival
(PFS) from the Emilia pivotal trial of 9.6 months (16).
The cases presented here showed complete responses to T-
DM1 which are maintained after 135 and 87 weeks, respectively,
from T-DM1 starting. The first patient is still on treatment, while
the second patient decided to interrupt it but still maintains the
excellent response.
These outlier responses led us to hypothesize some of the
mechanisms that might be responsible of these observations.
It is now well-accepted that the action of trastuzumab is, at
least in part, exerted through an immune mechanism known
as ADCC, consisting in tumor cell killing by immune effectors,
especially macrophages and natural killer cells (21).
It is therefore not surprising if several authors reported
hampered ADCC as a crucial mechanism of resistance to
trastuzumab (22, 23).
Indeed, in a pioneering study, Gennari et al. suggested
that ADCC activity of peripheral blood leukocytes was the
only statistically significant difference between trastuzumab-
responding and non-responding patients (23).
In this context, since natural killer cells play a major role
in the recognition and subsequent lysis of trastuzumab-coated-
her2+ tumor cells, it has been suggested that the efficiency of NK
systemmight actually be considered a hallmark of responsiveness
to trastuzumab (beano 2008). In addition, Trastuzumab-induced
immune activity relies also on the proper function of the antigen
presentation process (24).
Interestingly, it has also been reported that HER2+ breast
tumors enriched for immune function genes showed increased
relapse-free survival (RFS) after adjuvant trastuzumab as
compared to tumors not exhibiting these immune features (25).
As recently described, along with brain, eye, testes, and
placenta, immune privilege may take place also in the cutaneous
tissue, where several immunosuppressive phenomena take place.
Among others, the most significant involved mechanisms are (i)
the low or absent expression of MHC I-II molecules, involved
in the antigen presentation process; (ii) the inhibition of NK
activity, crucial effectors of the cytotoxic innate immune activity;
(iii) the upregulation of immune-checkpoints such as PD-L1, that
turn down lymphocyte T activity (26–28).
It is therefore conceivable that suchmitigation of the cytotoxic
immune activity physiologically occurring in the skin could
contribute to mediate resistance to trastuzumab.
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FIGURE 2 | Evolution of Case 2-cutaneous metastasis: (A) before TDM1 initiation, (B) after 4 courses of TDM1, (C) 9 months after TDM1 discontinuation.
FIGURE 3 | CD8/FOXP3 ratio from case 2 skin lesion. (A) CD8 antibody staining, (B) FOXP3 antibody staining. Ratio = 1,93.
Interestingly, we recently reported an analysis of immune
microenvironment across BC metastases, showing that skin
lesions exhibited higher FOXP3 levels and lower CD8/FOXP3
ratios as compared to other metastatic sites, especially in the
HER2+ subpopulations, thus further suggesting that cutaneous
tumor microenvironment may be unbalanced toward a more
immunosuppressive phenotype (29). As an illustration, we show
here the CD8/FOXP3 ratio in the skin lesion sample from case 2
patient. We observed CD8/FOXP3 ratio below 3, the cut-off that
was used to discriminate high vs. low CD8/FOXP3 ratio in our
previous publication (29) (Figure 3).
In this context, given its dual nature, the actual antitumor
effect of TDM1 might depend in a less extent on its trastuzumab
part, and conversely be predominantly due to its DM1
component. Accordingly, traditional resistance mechanisms to
trastuzumab may not be sufficient to hamper TDM1 action.
Therefore, if an immunosuppressive milieu might be crucial in
selecting trastuzumab-resistant tumor cells, it may not be enough
to contrast the antitumor effect of TDM1.
In addition, available data suggest that TDM1 may have
immunostimulating properties. Indeed, TDM1 has recently been
shown to potently enhance the immune system against tumor
cells, thanks to the combined effect of trastuzumab and emtasine
(30). In a mouse model of trastuzumab-resistant HER2+ BC,
T-DM1 was effective and was associated with an increase in
immune effector cells infiltrating the tumor. The most striking
results in terms of efficacy and immune activation were observed
with T-DM1 combined with CTLA-4/PD-1 blocking antibodies.
In conclusion, the cases presented here confirm the
efficacy of T-DM1 with current indication and describe
exceptional responses of isolated skin metastases. An intriguing
suggested hypothesis might be that the immunosuppressive
environment that might characterize some skin metastases
could be detrimental for trastuzumab, preventing it from
eliciting ADCC, but not for TDM1, that relies also on the
additional action of DM1. This hypothesis deserves further
research.
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